Lead: Dr Stephen Cunningham, Dr Iain Shaw
The biomimc development team is using both phage-display and SELEX techniques to develop (i) glycan specific antibody molecules and (ii) synthetic mimics of natural lectins to improve specificity to individual glycan epitopes. These mimics are in the form of either recombinant antibody fragments or as DNA and RNA aptamers. Increased specificity to glycan targets is essential in developing new diagnostic reagents and also in the analysis of targeted glycans present on recombinant biopharmaceuticals for bioprocessing QA and regulatory control. Once new biomimics are identified they are utilised and developed as both stand along bioassays and also incorporated into our custom array platforms, thereby increasing array reagent repertoire, broadening specificity, increasing signature information and providing additional HTP analysis markers.. Utilising our array and biomimic technologies we continue to advance the glyco-profiling cell surface to identify key changes that occur during disease processes. This approach is leading to new discoveries in the field of cancer diagnostics, allowing changes observed in immune cells during disease stages to be monitored, leading to novel disease biomarkers and enhanced informative markers of cell state. These tools are also being employed in the field of regenerative medicine to overcome issues with regard to transplant rejection.